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Introduction
Atrial septal defect (ASD) is one of the most common 
congenital heart diseases (CHDs) and accounts for the 
most common CHD in adults (1). There has been a shift 
of paradigm for therapeutic strategy of ASD over the last 
decades. Techniques and devices for transcatheter treatment 
have been evolved and refined; as a result, device closure 
of ASD is currently accepted as the treatment of choice 
in most patients with secundum ASD, showing excellent 
efficacy as well as lower complication rate comparing to 
surgery (2,3).
Extensive experiences have verified safety and usefulness 
of the procedure, and established general principle for 
device closure of ASD including patient selection, peri-
procedural assessment as well as procedural technique 
with various measures to prevent potential complications. 
However, unanticipated difficulties and un-negligible risks 
may be encountered during this “usually straightforward” 
procedure, and every effort has to be made to promote the 
efficacy and safety of the procedure on the basis of accurate 
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knowledge for procedural principles, solutions for specific 
problems as well as characteristic features of available 
devices. 
Principles and issues of device closure of ASD 
Patient selection is an important initial step for a successful 
treatment. Procedure in the catheterization laboratory 
may be summarized stepwise; (I) hemodynamic study and 
assessment of morphologic characteristics of the defect; 
(II) establishment of procedural strategy including 
procedure-guiding modality and equipment to be used; 
(III) selection of optimal type and size of device; (IV) device 
implantation with cautions for potential complications 
including air embolism, damage to cardiac/vascular 
structures; (V) post-implantation assessment of the final 
result. After a successful procedure, appropriate patient 
education and follow-up are also essential parts of the 
treatment. Details and special considerations for each step 
of the procedure have well been described previously (4). 
There are individual issues which are often in debate 
including procedure-guiding modalities, sizing the defect, 
and closing complex defects. 
Issues on imaging guidance and defect sizing
Although there have been studies reporting device closure 
guided only by either fluoroscopy or echocardiography 
(5-7), it is generally recommended to perform the 
procedure under both fluoroscopic and echocardiographic 
guidance. For echocardiographic guidance, transesophageal 
echocardiography (TEE) has long been the standard 
modality for ASD closure.  However,  intracardiac 
echocardiography (ICE) is gradually replacing the role of 
TEE recently. Transthoracic echocardiography (TTE) may 
also be used especially in patients with good windows for 
echocardiography such as small children (8). 
There has been debate on the necessity of balloon sizing 
for selection of device size. Balloon sizing may be skipped 
in suitable defects with sufficient surrounding rims (9); 
however, it has long been regarded as an essential step of 
the procedure (10). Indeed, balloon sizing may provide 
more information than averaged size of the defect including 
compliance of surrounding rims and presence of additional 
defect. 
While the balloon stretched diameter or balloon 
occlusive diameter were used in balloon sizing in the 
past, currently stop flow diameter (SFD) is recommended 
as the standard measurement to avoid oversizing (11). 
In self-centering devices such as the Amplatzer Septal 
Occluder (ASO) (St. Jude Medical, St. Paul, MN, USA), 
the recommended device size is the same or slightly larger 
(<2 mm) than the SFD. Nevertheless, the selection for 
device size should be individualized considering deficiency 
of rims, spatial relationship with nearby cardiac structures 
and size of the heart. In cases with aortic rim deficiency, 
the usual recommendation is to avoid an “oversized” 
device because of the potential risk of erosion (11). On 
the other hand, in cases with inferior vena cava (IVC) rim 
deficiency with higher risk of device embolization, use of 
an “undersized” device should be avoided. In case of using a 
non-self-centering device such as the Gore Septal Occluder 
(GSO) (WL Gore & Associates, Inc., Flagstaff, AZ, USA), a 
device twice the size of the defect is recommended (12), and 
the GSO is not recommended for defects >18 mm (13). 
Complex lesions
Large defect
Large size of the defect may be the most common cause 
of difficulties in ASD closure using a device. The main 
problems are prolapse of left atrial (LA) disk of the device 
into the right atrium (RA) before proper positioning in the 
septum (14) and difficulty in sizing the defect. Device size is 
frequently selected by estimation rather than measurement 
of balloon diameter due to non-visualization of the whole 
defect in a single echocardiographic plane, difficulty in 
stabilization of the sizing balloon (melon-seeding or milking) 
and unavailability of sizing balloon larger than 34 mm.
Various modified implantation techniques have been 
suggested to overcome the problem with LA disk prolapse 
(Table 1). An operator should be familiar with his/her own 
technique to overcome this problem. The balloon-assisted 
technique may be helpful even in cases when other methods 
failed. 
Rim deficiencies (Figure 1A,B,C,D,E)
Deficiency in the surrounding rim(s) is frequently associated 
with large defects, and may potentially increase the risk 
of complications such as device embolization, erosion and 
encroachment of device onto nearby cardiac structures. 
Aortic rim (antero-superior rim, Figure 1A) deficiency is 
most common rim deficiency (25) and device implantation 
is frequently interfered by LA disk prolapse. Erosion 
risk is higher in aortic rim deficiency as well as device 
oversizing (11), thus device selection has to be refrained 
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from undue oversizing. 
IVC rim (posteroinferior rim, Figure 1B) deficiency 
is second most common among rim deficiencies and 
associated with higher risk of device embolization (26). In 
case with this rim deficiency, under-sizing of the device may 
further increase the risk of device embolization, and should 
be avoided. It is difficult to visualize IVC rim with TEE 
guidance, so ICE is preferable imaging modality in patients 
with IVC rim deficiency (27); however, so called ‘modified 
retroflexed view’ may be helpful to visualize IVC rim with 
TEE guidance (28).
Superior vena cava (SVC) rim (posterosuperior rim, 
Figure 1C) deficiency is a rare condition and may interfere 
with device positioning (29). When the rim deficiency is 
extended from SVC rim to aortic rim, this indicates the 
defect is located superiorly in the atrial roof and may carry 
higher risk of erosion (11,30). 
In case with posterior rim (Figure 1D) deficiency, the 
feasibility of device closure may be decided by the extent of 
rim deficiency (Figure 2). In the presence of rim deficiency 
in large area from IVC to posterior rim, the risk of device 
embolization is very high and this condition may preclude 
device closure. 
In atrioventricular valve rim (Figure 1E) deficiency, 
encroachment of device onto the mitral and/or tricuspid 
valve is a potential problem. This is a concern especially in 
infants and young children because of the inherent design of 
Amplatzer-type devices which have a relatively larger disk-
rim width in smaller devices. In case of device encroachment 
onto the valve, it is generally recommended not to implant 
a device. There is an extremely rare documented case of 
erosion on mitral valve (31).
Multiple defects
There are many challenges or considering factors when 
planning closure of multiple ASDs, including numbers/
size of the defect, location/spatial relationship between 
the defects, properties of supporting rims or intervening 
septum as well as presence of septal aneurysm. Ultimately, 
understanding the accurate anatomy and properties of 
surrounding/intervening rims of multiple defects is the 
cornerstone of successful device closure. To overcome 
these problems, proper use of real time 3-dimensional 
(RT3D) echocardiography may be helpful (32,33). RT3D 
echocardiography enables visualization of the wide ranged 
septum in a single view in the echocardiography and 
provides instantaneous understanding of the anatomy 
as well as identification of complex morphology and 
spatial relationship between multiple defects (Figure 3). 
Temporary balloon occlusion test may also be useful to 
investigate compliance of surrounding rims and intervening 
septum, as well as to predict changes of the defects and 
rims after device implantation. Also, a careful observation 
of fluoroscopic images with balloon sizing may provide 
additional information on the spatial relationship between 
the defects and intervening septum (Figure 4). In case 
of device closure of multiple defects using multiple 
devices, the optimal combination of devices based on the 
comprehensive information from RT3D echocardiography 
and balloon occlusion test is required to prevent unfavorable 
interference between multiple devices (Figure 5). Usually, 
a small additional defect adjacent to a larger defect (<7 mm 
in distance) can also be closed by implantation of a single 
device in the major defect (34). When the additional defect 
is also sizable or defects are in distance each other, use of 
multiple devices is required. For multi-fenestrated defects 
with a large septal aneurysm, patch-like closure using a 
non-self-centering device may be a good option (Figure 6).
Currently available devices for ASD closure 
(Figure 7)
ASO (Figure 7A, Table 2)
The ASO is the first self-expanding double-disk device 
Table 1 Various technical modifications to prevent left atrial disk 
prolapse during device positioning
1. Waist deployment in LA 
2. Rotation of sheath in LA (15)
3. Bending (pre-shaping) (15)/cutting of sheath tip (16)
4. RUPV technique (14,17)
Hypomochlion technique, LA roof technique 
5. LUPV technique (14)
6. Stiff sheath (dilator) technique (18)
7. Use of Hausdorf-Lock sheath (14)
8. Balloon-assisted technique (19-21)
9. Straight side-hole delivery sheath technique (22)
10. Steerable sheath technique (23)
11. Use of JR coronary guiding catheter (24)
LA, left atrium; LUPV, left pulmonary vein; RUPV, right upper 
pulmonary vein; JR, Judkin’s right. 
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with central connecting waist composed of nitinol-wire-
mesh. The disks and waist were sewn with a Dacron patch 
to promote complete occlusion and endothelialization. 
The device allowed easy and straightforward deployment 
due to its self-centering, repositionable, and recapturable 
characteristics. The ASO solved many limitations of 
previous devices such as the non-negligible rate of 
residual shunt and frame fracture, and is regarded as a 
prototype device for many newer devices. The device size is 
determined by the waist size; there are 27 device sizes from 
4 to 40 mm (in 1-mm increments between 4 to 20 mm and 
2-mm increments between 20 to 40 mm). The corresponded 
delivery sheath sizes range from 6 to 12 French (Fr). 
Initial study showed excellent success rate of 95.7% 
and low major and total adverse effect of 1.6% and 
7.2% respectively (3). The subsequent MAGIC study 
and IMPACT registry reported compatible success 
and complication (35,36). Largest experience has been 
accumulated in ASO, but the risk of erosion has been 
issued (37) since it can be fatal and may occur delayed. The 
exact rate is still unclear, but the estimated rate is about 
0.1 to 0.3 (38). Reported risk factors include aortic rim 
deficiency, superiorly located ASD, over-sizing of device, 
septal malalignment, dynamic ASD and lower patient 
weight: device size ratio (11,30,37-40), and the most 
probable mechanism is abrasion due to seesaw movement 
according to the cardiac cycle (37), although the exact 
mechanism is unclear or not known. 
Recommendat ions  to  avoid  eros ion should be 
fo l lowed (11)  and  comprehens ive  eva luat ion  by 
echocardiography during follow-up is warranted (30,40).
The ASO “cribriform” is a specially designed non-
self-centering device for multi-fenestrated defects with 
4 available sizes from 18 to 40 mm. 
Figure 1 The locations of rim deficiencies: (A) aortic rim, (B) IVC rim, (C) SVC rim deficiency, (D) posterior rim, (E) atrioventricular valve 
rim. SVC, superior vena cava; IVC, inferior vena cava; ASD, atrial septal defect; CS, coronary sinus; AAo, ascending aorta; TV, tricuspid 
valve. 
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Occlutech Figulla Flex II ASD Occluder (Figure 7B)
Figulla Flex II ASD Occluder (FSO, Occlutech GmbH, 
Jena, Germany) is the third generation Occlutech device for 
ASD closure with a flexible titanium-oxide coated nitinol-
mesh and double-disk design similar to ASO. FSO has 
minimized metal contents especially in the LA disk and no 
clamping hub on the LA disk, which may provide more 
flexible and less traumatic feature. The FSO has a distinct 
release mechanism resembling a bioptome which enables 
flexible movement between the device and delivery cable. 
The delivery cable is also shapeable for a better alignment 
between the device and septum. 
Figure 2 Illustration of feasible (A), borderline (B) and unfeasible (C) defect for device closure in posterior rim deficiency. For the defects 
with posterior rim deficiency, the extent of rim deficiency determines feasibility of device closure, so the clear anatomic definition is very 
important. SVC, superior vena cava; IVC, inferior vena cava; AAo, ascending aorta; TV, tricuspid valve.
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There are 20 device size options from 4 to 40 mm 
(1–1.5-mm increments between 4 and 21 mm, 3-mm 
increments between 21 and 39 mm, and 40 mm). 
Retrospective comparison studies showed a compatible 
efficacy and safety comparing to ASO (41,42). The largest 
study with FSO, the IRFACODE study, showed a 98% 
success rate in 1395 patients and a 97.3% complete closure 
rate at 1 year (43). The major complication rate was 
minimal (n=8, <1%). Erosion has not yet been reported 
with this device. The disadvantages are its relatively limited 
size options (20 vs. 27 sizes in ASO) and requirement of a 
slightly larger delivery sheath than in ASO devices. 
A fenestrated device for closure of ASD with pulmonary 
hypertension or risk of masked left ventricular restriction is 
available on an order-made basis. 
GSO (Figure 7C)
The GSO is a non-self-centering double disk device 
composed of platinum filled nitinol wire framework 
covered with an expanded polytetrafluoroethylene (ePTFE) 
membrane to promote rapid endothelialization. The GSO 
is preloaded as a package of the device and whole delivery 
system. The delivery system has improved for easier delivery 
and position compared to that of the previous Helex Septal 
Occluder (HSO). There are 4 device sizes from 15 to 
30 mm with 5-mm increments. It is generally recommended 
that the device size should be more than twice the defect 
size and the GSO is not suitable for defects over 18 mm due 
to the non-self-centering feature. Owing to its flexibility 
with minimal metal content which may prevent erosion, 
the device is preferred to close smaller defects especially 
Figure 4 Careful observation of fluoroscopic image with balloon sizing may provide additional anatomic information on the defects and 
intervening septum.
Figure 3 Real time 3-dimensional (RT3D) echocardiography is very useful to assess morphologic characteristics for multiple defects. Note 
the similarity between the realistic image from RT3D echocardiography (A) and actual image of the defect from the surgical field (B).
A B
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with aortic rim deficiency or those in small children (44). 
Clinical studies verified efficacy and safety of this device in 
closing ASDs with various morphologies such as aortic rim 
deficiency, septal aneurysm and multiple defects in selected 
patients with feasible anatomy (12,13,45).
The Gore Cardioform ASD Occluder (GAO) is a self-
centering version of GSO which consists of a helical nitinol-
wire frame covered with ePTFE to treat larger ASDs. The 
available sizes are 27, 32, 37, 44, and 48 mm and designed 
to treat defects from 8 to 35 mm. Although this device is 
not commercially available yet, the initial clinical result 
showed the safety and efficacy of the GAO (46). The risk 
factor for procedural failure in GAO implantation was a 
larger defect size, especially a size larger than 27 mm by 
balloon sizing. 
CeraFlex ASD Occluder (Figure 7D)
CeraFlex (LifeTech Scientific Co., Shenzhen, China), the 
4th generation ASD device from LifeTech, is a nitinol-wire-
Figure 5 Advantages of real time 3-dimensional (RT3D) transesophageal echocardiography (TEE) guidance in device closure of multiple 
ASDs. True anatomy of multiple defects is difficult to understand by 2-dimensional (2D) TEE images even in multiple views (A,B) with color 
flow Doppler (C), however the anatomic characteristics including number of the defect, shape/size of each defect and spatial relationship 
between the defects are clearly shown on RT3D image (D). RT3D echocardiography also provides excellent images during balloon sizing (E) 
and post-assessment of the device position (F,G). LA, left atrium; RA, right atrium.
LA LA LA
RA
RA RA
A B C
D E
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G
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mesh device coated with titanium nitride. This device is 
preloaded as a package and has a similar feature to other 
nitinol-wire-mesh devices such as self-expanding property 
and double-disk design with central waist. Ceraflex has 
couple of shared features with FSO; a coated surface of 
nitinol-wire, flexible connection between the device and 
delivery cable, and no hub on LA disk. A total of 19 sizes are 
available from 6 to 42 mm with 2-mm increments, and the 
delivery sheath sizes range from 8 to 14 Fr. A comparative 
study between Ceraflex and ASO showed comparable 
success rate, safety and efficacy (47). The disadvantages are 
its relatively limited size options (19 vs. 27 sizes in ASO) 
and the requirement of a slightly larger delivery sheath than 
with ASO devices.
Cocoon Septal Occluder (Figure 7E)
The Cocoon Septal Occluder (Vascular Innovations Co., 
Nonthaburi, Thailand) is a self-expanding double-disk 
device consists of a nano-platinum coated nitinol device 
filled with polypropylene fabric. The device is quite similar 
to ASO in terms of device design except for the nano-
platinum-coated surface which prevents nickel release 
to the blood stream (48), promotes biocompatibility and 
enhances radio-opacity on fluoroscopy. There are 17 device 
options ranging from 8 to 40 mm with 2-mm increments 
and the delivery sheath sizes range from 7 to 14 Fr. 
European multicenter study reported an excellent result 
with procedural success rate of 100% and no complication 
in 92 patients (49). This device has been described as softest 
and lightest currently available device with less metal-to-
septum ratio than other devices (49). The disadvantages are 
its relatively limited size options (17 vs. 27 sizes in ASO) 
and the requirement of a slightly larger delivery sheath than 
with ASO devices.
Nit-Occlud ASD-R (Figure 7F) 
The Nit-Occlud ASD-R (NOA-R) (pfm Medical, Cologne, 
Germany) is a double-disk, self-expandable, self-centering 
device; however, the device characteristics are quite different 
from other nitrol-mesh devices. NOA-R has reduced 
amount of metal on the left atrial disk without  clamping 
or screwing hub on either side of the atrial disks and has a 
“reverse configuration” of the single-nitinol-layer on the 
LA disk (the “R” on the product name indicates this). These 
characteristics may allow more flexible and conformable 
device positioning on the septum. The release mechanism is 
unique as it is “snare-like,” which includes a central locking 
wire and a pusher with a distal wire noose (50). A total of 12 
sizes are available from 8 to 30 mm with 2-mm increments, 
and the delivery sheath sizes range from 8 to 14 Fr. 
A multicenter study showed a 98.6% (73/74 patients) 
success rate with one case of complete heart block (50). 
Device retrieval is more difficult because of the no-hub 
design (50); however, retrieval of the device may be feasible 
using a special technique (snare and wire technique) with an 
oversized sheath (51). Two cases of erosion including one 
lethal case were reported (52,53). The disadvantages (are 
its relatively limited size options (12 vs. 27 sizes in ASO), 
and the requirement of a slightly larger delivery sheath than 
with ASO devices and inability to close larger defects. 
Figure 6 Patch-like closure using non-self-centering device is a good option for multi-fenestrated defects with a large septal aneurysm. 
Transthoracic echocardiography (A) and transesophageal echocardiography (B) shows multi-fenestrated defects with a large septal aneurysm. 
A 35mm cribriform device (C) was implanted in the center hole of the aneurysm instead of larger eccentric hole to achieve a complete 
coverage of base of the septal aneurysm. Follow-up echocardiography shows a patch-like closure of defects and septal aneurysm (D).
A B C D
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Figure 7 Currently available devices for atrial septal defect closure. (A) Amplatzer Septal Occluder; (B) Occlutech Figulla Flex II device; 
(C) Gore Cardioform Septal Occluder; (D) Cocoon Septal Occluder; (E) CeraFlex ASD device; (F) Nit Occlud ASD-R device; (G) Cardi-
O-Fix Septal Occluder; (H) Ultracept II ASD Occluder and (I) Carag Bioresorbable Septal occluder. 
Cardi-O-Fix Septal Occluder (Figure 7G)
The Cardi-O-Fix septal occluder (Starway Medical 
Technology, Beijing, China) is a self expandible double 
disk design device consists of nitinol wire mesh filled with 
polyester fabric sewn to waist and each disk. This device 
is structurally similar to the ASD, however this device has 
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Table 2 Comparison of commonly used devices 
Devices
Approval/distribution/No.  
of shipment or implantation
Advantages Disadvantages Considerations
Amplatzer 
Septal Occluder
FDA/Worldwide/>500,000 General familiarity Most of the reported cases 
of erosion
Adverse events have been 
extensively investigated
Largest experience with 
accumulated data including long-
term safety
Nickel release Non-self-centering 
version is also available 
(cribriform devices)
Widest range of sizes Stiff device-cable coupling 
—device jumping on release
Occlutech 
Figulla Flex II 
ASD Occluder
CE mark/>80 
countries/>50,000 
including previous 
generation devices
Soft and flexible braiding 
—conforms to the defect 
—may reduce erosion risk
Fewer available sizes Usually regarded as a 
softer device than ASO
Larger delivery sheaths Non-self-centering 
version is also available 
(uniform devices)
Less experience and data 
—lack of long term data 
Order-made fenestrated 
device is available
Flexible delivery system: 
50°angulation + shapeable cable  
—less tension and jump on 
release 
Less material, no hub on LA disk 
smaller RA hub
Titanium oxide coated surface
Gore Cardioform 
Septal Occluder
FDA (CE mark)/ 
15 countries/>8,000; 
>33,000 including HSO 
Less exposure of metal to blood 
stream
Cannot close >18 mm 
defect
Non-self-centering device
Softer device with less metal 
content; not likely cause erosion
Only 4 available sizes 
relatively larger delivery 
system for smaller defects
Thinner device profile Rigid coupling between 
device and control catheter 
before unlocking
Good alignment to the septum 
after locking of occluder (retrieval 
is still possible if mis-positioned)
Less experience and data 
—lack of long term data
Cocoon Septal 
Occluder
CE mark/22 
countries/>40,000
Nano-platinum coated surface 
—prevent nickel release  
—enhance radio-opacity and 
biocompatibility
Stiff device-cable coupling 
—device jumping on release
Usually regarded as a 
softer device than ASO
Softer and lighter device 
—may reduce erosion risk
Fewer available sizes 
Larger delivery sheaths
Less experience and data 
—lack of long term data
Table 2 (continued)
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two different versions of products with or without clamping 
hub on the LA disk. A total of 27 sizes are available from 
4 to 40 mm (1-mm increment between 4 to 20 mm and 
2-mm increment between 20 to 40 mm), and the delivery 
sheath sizes range from 7 to 14 Fr. A comparative study 
between this device and ASO showed comparable outcome 
and lower cost with Cardi-O-Fix device (US$ 4,100 vs. US$ 
5,900, P<0.001) (54). The disadvantages may include less 
experience/data with this device and the requirement of a 
slightly larger delivery sheath than with ASO. 
Ultracept II ASD Occluder (Figure 7H)
The last generation of CARDIA ASD closure device, the 
Ultracept II ASD Occluder (Cardia, Eagan, MN, USA) is 
a double-round disk, self-centering, low profile device. It 
has a nitinol frame with a polyvinyl alcohol (PVA) coating 
to reduce thrombus formation. A total of 15 sizes are 
available from 6 to 34 mm with 2-mm increments, and the 
delivery sheath sizes range from 9 to 11 Fr. Several cases of 
PVA-membrane perforation or degradation were reported 
(55-57), which were also reported with the previous 
genera t ion  dev ice  (58 ) .  Desp i te  comprehens ive 
investigations on the PVA membrane, the mechanism 
of degradation has not been identified. Some authors 
emphasized that the interventionist should be aware of this 
rare complication (57). 
Carag Bioresorbable Septal occluder (Figure 7I) 
Carag Bioresorbable Septal Occluder (CBRO) (CARAG 
AG, Baar, Switzerland) is a self-centering, double disk 
device without any metal framework, composed of poly 
lactic-co-glycolic acid (59). Endothelialization of the device 
seems to be completed within 3 months, while the device 
usually starts to be resorbed after 6 months and completely 
resolved within 2 years. CBRO has 3 size options: small for 
4–12 mm defects, intermediate for 13–20 mm, and large for 
21–25 mm. Preliminary data showed an excellent efficacy 
of CBRO with successful outcome in all ten patients, 4 with 
ASD and 6 with patent foramen ovale (60). 
Conclusions
Transcatheter closure of secundum ASD is the treatment of 
choice in most patients with feasible anatomy. An operator 
should be familiar with principles of the procedure, 
solutions for procedural difficulty, cautions to avoid 
complications and detailed knowledge on the available 
equipments to promote safety and efficacy of this versatile 
therapy. 
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